Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037.
Calibr, a Division of Scripps Research, La Jolla, California 92037.
J Biol Chem. 2019 Oct 11;294(41):15176-15181. doi: 10.1074/jbc.AC119.010236. Epub 2019 Sep 3.
Skeletal muscle myosin has potent procoagulant activity that is based on its ability to enhance thrombin generation due to binding coagulation factors Xa and Va and accelerating prothrombin activation. A well-studied myosin inhibitor that binds to myosin's neck region inhibits myosin-dependent prothrombin activation. Hence, to identify a potential binding site(s) on skeletal muscle myosin for factor Xa, 19 peptides (25-40 residues) representing the neck region, which consists of a regulatory light chain, an essential light chain, and a heavy chain (HC), were screened for inhibition of myosin-supported prothrombin activation. Peptide HC796-835 comprising residues 796-835 of the heavy chain strongly inhibited myosin-enhanced prothrombin activation by factors Xa and Va (50% inhibition at 1.2 μm), but it did not inhibit phospholipid vesicle-enhanced prothrombin activation. Peptide inhibition studies also implicated several myosin light chain sequences located near HC796-835 as potential procoagulant sites. A peptide comprising HC796-835's C-terminal half, but not a peptide comprising its N-terminal half, inhibited myosin-enhanced prothrombin activation (50% inhibition at 1.2 μm). This inhibitory peptide (HC816-837) did not inhibit phospholipid-enhanced prothrombin activation, indicating its specificity for inhibition of myosin-dependent procoagulant mechanisms. Binding studies showed that purified factor Xa was bound to immobilized peptides HC796-835 and HC816-837 with apparent values of 0.78 and 1.3 μm, respectively. In summary, these studies imply that HC residues 816-835 in the neck region of the skeletal muscle myosin directly bind factor Xa and, with contributions from light chain residues in this neck region, contribute to provision of myosin's procoagulant surface.
骨骼肌肌球蛋白具有很强的促凝活性,这是基于其结合凝血因子 Xa 和 Va 的能力,并加速凝血酶原激活,从而增强凝血酶的生成。一种研究得很好的肌球蛋白抑制剂,它结合肌球蛋白的颈部区域,抑制肌球蛋白依赖的凝血酶原激活。因此,为了确定骨骼肌肌球蛋白上因子 Xa 的潜在结合位点,筛选了 19 个肽(25-40 个残基),代表颈部区域,由调节轻链、必需轻链和重链(HC)组成,以抑制肌球蛋白支持的凝血酶原激活。肽 HC796-835 包含重链的残基 796-835,强烈抑制因子 Xa 和 Va 增强的肌球蛋白促凝血酶原激活(在 1.2 μm 时 50%抑制),但不抑制磷脂囊泡增强的凝血酶原激活。肽抑制研究还暗示了位于 HC796-835 附近的几个肌球蛋白轻链序列是潜在的促凝部位。包含 HC796-835 C 端一半的肽,但不包含其 N 端一半的肽,抑制肌球蛋白增强的凝血酶原激活(在 1.2 μm 时 50%抑制)。这种抑制肽(HC816-837)不抑制磷脂增强的凝血酶原激活,表明其特异性抑制肌球蛋白依赖的促凝机制。结合研究表明,纯化的因子 Xa 与固定化肽 HC796-835 和 HC816-837 结合,表观值分别为 0.78 和 1.3 μm。总之,这些研究表明,颈部区域的骨骼肌肌球蛋白 HC 残基 816-835 直接结合因子 Xa,并与该颈部区域的轻链残基共同提供肌球蛋白的促凝表面。